Gradient Investments LLC lowered its stake in shares of Sanofi (NASDAQ:SNY – Get Rating) by 3.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,735 shares of the company’s stock after selling 327 shares during the quarter. Gradient Investments LLC’s holdings in Sanofi were worth $448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently modified their holdings of the company. GHP Investment Advisors Inc. bought a new stake in Sanofi during the first quarter worth about $26,000. Fairfield Bush & CO. bought a new stake in Sanofi during the first quarter worth about $26,000. Pinnacle Bancorp Inc. boosted its stake in Sanofi by 49.0% during the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company’s stock worth $30,000 after acquiring an additional 193 shares in the last quarter. Ahrens Investment Partners LLC bought a new stake in Sanofi during the first quarter worth about $31,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Sanofi during the first quarter worth about $32,000. Hedge funds and other institutional investors own 10.33% of the company’s stock.
Sanofi Stock Up 1.5 %
Shares of SNY stock opened at $40.67 on Friday. Sanofi has a 12 month low of $39.49 and a 12 month high of $58.10. The stock has a market cap of $103.10 billion, a P/E ratio of 13.51, a P/E/G ratio of 1.01 and a beta of 0.53. The company has a current ratio of 1.29, a quick ratio of 0.34 and a debt-to-equity ratio of 0.22. The company has a 50 day simple moving average of $44.91 and a two-hundred day simple moving average of $49.21.
Sanofi (NASDAQ:SNY – Get Rating) last announced its earnings results on Thursday, July 28th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.07. The business had revenue of $10.78 billion during the quarter, compared to analysts’ expectations of $10.32 billion. Sanofi had a net margin of 16.60% and a return on equity of 25.99%. On average, research analysts expect that Sanofi will post 4.14 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages have recently issued reports on SNY. Credit Suisse Group upped their target price on shares of Sanofi from €105.00 ($107.14) to €110.00 ($112.24) and gave the stock an “outperform” rating in a research note on Friday, July 22nd. JPMorgan Chase & Co. upped their target price on shares of Sanofi from €105.00 ($107.14) to €115.00 ($117.35) in a research note on Monday, August 1st. StockNews.com upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 14th. Morgan Stanley lowered their price objective on shares of Sanofi from €112.00 ($114.29) to €93.00 ($94.90) in a research report on Thursday, September 8th. Finally, Kepler Capital Markets downgraded shares of Sanofi from a “buy” rating to a “hold” rating and lowered their price objective for the company from €120.00 ($122.45) to €89.00 ($90.82) in a research report on Wednesday, August 24th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.38.
Sanofi Company Profile
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
See Also
Receive News & Ratings for Sanofi Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sanofi and related companies with MarketBeat.com’s FREE daily email newsletter.
